Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Intersect ENT, Inc. (NASDAQ: XENT).

Full DD Report for XENT

You must become a subscriber to view this report.


Recent News from (NASDAQ: XENT)

Intersect ENT's (XENT) CEO Lisa Earnhardt on Q2 2018 Results - Earnings Call Transcript
Intersect ENT Inc. (XENT) Q2 2018 Earnings Conference Call August 1, 2018 4:30 PM ET Executives Jeryl Hilleman – Chief Financial Officer Lisa Earnhardt – President and Chief Executive Officer Analysts Robbie Marcus – J.P. Morgan Bob Hopkins – Ban...
Source: SeekingAlpha
Date: August, 01 2018 22:14
Midday Gainers / Losers (08/01/2018)
Gainers:  TCS +39% . NSYS +35% . RXII +26% . SODA +22% . NMRD +21% . GDS +19% . DHXM +19% . MRCY +19% . QUAD +19% . RCKY +18% . More news on: The Container Store Group, Inc., Nortech Systems Incorporated, RXI Pharmaceuticals Corporation, Stocks on the m...
Source: SeekingAlpha
Date: August, 01 2018 12:45
Premarket Losers as of 9:05 am (8/1/2018)
KEYW   -28%  on Q2 earnings . More news on: KEYW Holding, Diebold Nixdorf, Cellectar Biosciences, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: August, 01 2018 09:20
Intersect ENT beats by $0.03, misses on revenue
Intersect ENT (NASDAQ: XENT ): Q2 EPS of -$0.14 beats by $0.03 . More news on: Intersect ENT, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 01 2018 08:58
Intersect ENT Reports Second Quarter 2018 Results
Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the second quarter ended June 30, 2018. On April 1, 2018, the company announced commencement of the commercial l...
Source: Business Wire
Date: August, 01 2018 08:18
Minerva Neurosciences Elects Jeryl Hilleman to Board of Directors
WALTHAM, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the election of Jeryl Hilleman to the Board of Dir...
Source: GlobeNewswire
Date: July, 17 2018 16:05
Intersect ENT to Report Second Quarter 2018 Financial Results
Intersect ENT, Inc. (NASDAQ: XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that it will release financial results for its second quarter on August 1, 2018. The company expects to issue the release at approximately 4...
Source: Business Wire
Date: July, 11 2018 17:19
Faruqi & Faruqi, LLP is Investigating Intersect ENT, Inc. (XENT) on Behalf of its Shareholders
NEW YORK , June 18, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential breaches of fiduciary duty by the board of directors at Intersect ENT, Inc. ("Intersect" or the "Company") (NASDAQ: XENT). Request more info...
Source: PR Newswire
Date: June, 18 2018 12:11
Intersect ENT to Present at William Blair & Company 38th Annual Growth Stock Conference
Intersect ENT, Inc. (Nasdaq: XENT ) today announced that management will present at the 38 th Annual William Blair Growth Stock Conference. The presentation is scheduled for June 12, 2018 at 11:30 a.m. CT at the Four Seasons Hotel in Chicago, Ill. A webcast will be available online...
Source: Business Wire
Date: May, 29 2018 16:05
Intersect ENT's (XENT) CEO Lisa Earnhardt on Q1 2018 Results - Earnings Call Transcript
Intersect ENT Inc. (XENT) Q1 2018 Earnings Conference Call May 01, 2018 04:30 PM ET Executives Jeri Hilleman - Chief Financial Officer Lisa Earnhardt - President and Chief Executive Officer Analysts Chris Pasquale - Guggenheim Kristen Stewart - Deutsche Bank Ravi Misra - ...
Source: SeekingAlpha
Date: May, 01 2018 20:39

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0829.3028.9030.1028.75249,407
2018-05-1740.3039.2040.4039.00233,039
2017-03-1014.9514.9515.226614.850512,793
2017-03-0914.6514.8515.8514.55321,004
2017-03-0814.2014.6514.8514.10223,823

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-0728,96248,56459.6368Short
2018-12-0630,20681,67336.9841Short
2018-12-0434,225114,32629.9363Cover
2018-12-0329,57294,85231.1770Cover
2018-11-3015,84391,12917.3852Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on XENT.


About Intersect ENT, Inc. (NASDAQ: XENT)

Logo for Intersect ENT, Inc. (NASDAQ: XENT)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: XENT)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 03 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 01 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 23 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 23 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: February, 28 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: February, 28 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: February, 27 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 08 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 05 2018

       

       


      Daily Technical Chart for (NASDAQ: XENT)

      Daily Technical Chart for (NASDAQ: XENT)


      Stay tuned for daily updates and more on (NASDAQ: XENT)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: XENT)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in XENT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of XENT and does not buy, sell, or trade any shares of XENT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/